Novel ‘Molecular Glue’ Strategy Offers Hope for Preserving Beta Cell Function in Type 2 Diabetes
New York, NY – March 5, 2025 – A groundbreaking study published today in Nature Communications details a novel therapeutic approach to protecting insulin-producing beta cells from the damaging effects of glucolipotoxicity, a key driver of Type 2 Diabetes (T2D) progression. Researchers at the Icahn School of Medicine at Mount Sinai have identified and successfully tested “molecular glues” that modulate a critical cellular process,offering a potential pathway to slow,and possibly even prevent,the debilitating loss of beta cell function characteristic of the disease. This research represents a notable paradigm shift in diabetes treatment, moving beyond blood sugar management towards direct beta cell preservation.
The Challenge of Beta Cell Failure in Type 2 Diabetes
Type 2 Diabetes affects over 500 million people globally and is characterized by the body’s inability to effectively use insulin (insulin resistance) and/or a decline in the function and number of beta cells within the pancreas.These beta cells are responsible for producing insulin, the hormone that regulates blood glucose levels. Prolonged exposure to high glucose and fatty acid levels – a condition known as glucolipotoxicity – progressively impairs beta cell function, ultimately leading to cell death and worsening diabetic control. Current treatments largely focus on managing blood sugar after damage has occurred, often requiring increasing doses of insulin and failing to address the root cause of the disease.
“For decades, the field has been searching for ways to protect these vital insulin-producing cells,” explains Dr. Donald K. Scott,PhD,Professor of Medicine (Endocrinology,Diabetes and Bone Disease) at the Icahn School of Medicine. “Our findings suggest a completely new strategy for preserving beta cell function, one that could complement existing therapies and considerably alter the trajectory of the disease.”
Unlocking Beta Cell Protection with Molecular Glues
The research centers around a crucial transcription factor called carbohydrate response element binding protein (ChREBP). ChREBP exists in two forms, ChREBPα and ChREBPβ, and plays a vital role in glucose metabolism. The mount Sinai team discovered that under glucolipotoxic conditions, ChREBPα inappropriately translocates to the cell nucleus, triggering the overproduction of ChREBPβ. This excess ChREBPβ actively disables and ultimately kills beta cells.
The breakthrough lies in the growth of small molecule “molecular glues” – compounds designed to enhance the interaction between ChREBPα and 14-3-3 proteins. These 14-3-3 proteins normally anchor ChREBPα within the cytoplasm of the beta cell. By strengthening this interaction, the molecular glues effectively prevent ChREBPα from entering the nucleus and initiating the harmful cascade leading to ChREBPβ overproduction.
“We’ve demonstrated, for the first time, that it’s possible to use small molecules to precisely tune ChREBP activity,” says lead author Liora S.Katz, PhD, Associate Professor of Medicine (Endocrinology, Diabetes and Bone Disease) at the Icahn School of Medicine. “this is an exciting step forward, as transcription factors like ChREBP have historically been considered ‘undruggable’ targets.”
Promising Results in Human beta Cells
When tested on primary human beta cells, the molecular glues demonstrably reduced the toxic effects of glucolipotoxicity, preserving both beta cell function and their specialized identity. This preservation of function is critical, as maintaining the cells’ ability to accurately sense glucose and release insulin is paramount for effective blood sugar control.
Looking Ahead: Clinical Translation and Broader Implications
The research team is now focused on refining these compounds and preparing them for preclinical studies in animal models of diabetes. These studies will focus on optimizing the molecular glues for therapeutic efficacy and assessing their safety profile. The ultimate goal is to translate these findings into a clinical therapy that can be used to prevent or delay the progression of Type 2 Diabetes.
Beyond diabetes, the success of this approach highlights the broader potential of molecular glues as a therapeutic strategy for modulating protein-protein interactions in a wide range of diseases. This innovative technique could unlock new treatment avenues for conditions previously considered intractable.
Collaboration and Funding
This research was a collaborative effort involving teams from the Icahn School of Medicine at Mount Sinai, Eindhoven University of Technology in the Netherlands, and the University of Duisburg-Essen in Germany. Funding was provided by the National Institutes of Health (NIH/NIDDK R01DK130300 and P30DK020541), the European Research council (ERC Advanced Grant PPI-Glue (101098234)), the Netherlands Ministry of Education,